With more than 20 years of biopharmaceutical experience ranging from research to bringing products to market, Dr. Kristin Yarema was named Atara’s Chief Commercial Officer in February of 2020.
Kristin came to Atara after serving as Amgen’s Vice President & Therapeutic Area Head, Global Product Strategy & Commercial Innovation, Hematology and Oncology. In her seven years at Amgen, Dr. Yarema strategically managed the company’s pipeline in small molecule and immuno-oncology for hematological malignancies, such as multiple myeloma, leukemias, and lymphomas, and was recognized as having the top therapeutic area in 2018 while leading the Cardiovascular, Metabolism and Neuroscience business unit.
Prior to joining Amgen, Dr. Yarema held global roles for Novartis and McKinsey & Company, where she led project teams for companies across the U.S., Europe, and Asia.
Dr. Yarema graduated from University of California, Berkeley with a Ph.D. in Biochemical/Biomedical Engineering and Stanford University with a B.S. in Chemical Engineering with Distinction and B.A. in English with Distinction. In addition, she has served on the Board of Directors for the Celiac Disease Foundation, the U.S.-based patient-advocacy group.
Dr. Yarema is proficient in Advanced German and basic French and in her free time, enjoys cycling, music, food, wine, yoga and travel.
What is Kristin Yarema's net worth?
The estimated net worth of Kristin Yarema is at least $44,892.00 as of June 14th, 2021. Dr. Yarema owns 3,741 shares of Atara Biotherapeutics stock worth more than $44,892 as of November 17th. This net worth approximation does not reflect any other assets that Dr. Yarema may own. Learn More about Kristin Yarema's net worth.
How do I contact Kristin Yarema?
Has Kristin Yarema been buying or selling shares of Atara Biotherapeutics?
Kristin Yarema has not been actively trading shares of Atara Biotherapeutics during the last quarter. Most recently, on Monday, June 14th, Kristin Yarema bought 1,293 shares of Atara Biotherapeutics stock. The stock was acquired at an average cost of $364.25 per share, with a total value of $470,975.25. Following the completion of the transaction, the insider now directly owns 3,741 shares of the company's stock, valued at $1,362,659.25. Learn More on Kristin Yarema's trading history.
Who are Atara Biotherapeutics' active insiders?
Are insiders buying or selling shares of Atara Biotherapeutics?
During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 13,471 shares worth more than $159,765.27. The most recent insider tranaction occured on August, 16th when CEO Pascal Touchon sold 3,038 shares worth more than $20,141.94. Insiders at Atara Biotherapeutics own 3.7% of the company.
Learn More about insider trades at Atara Biotherapeutics. Information on this page was last updated on 8/16/2024.
